Chinese companies to make generic version of Pfizer's oral COVID-19 pill | 中國公司將生產輝瑞口服 新冠 藥丸的仿製藥 скачать в хорошем качестве

Chinese companies to make generic version of Pfizer's oral COVID-19 pill | 中國公司將生產輝瑞口服 新冠 藥丸的仿製藥

👏If you see a video from this channel, please click it and watch to the end. This will help increase YouTube recommendations for the video and channel. ******************************************************** The first shipment of Pfizer's anti-viral treatment, Paxlovid, has arrived in China on Thursday and five Chinese companies will manufacture the generic version of the oral pill. China's drug regulator granted conditional approval for the imports of Pfizer's Paxlovid COVID-19 pill on Feb 11. The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate COVID-19 symptoms and who are at a higher risk of becoming more seriously ill, according to the National Medical Products Administration. It can be given to patients who, for instance, are in old age or have chronic renal diseases, diabetes, cardiovascular diseases and chronic lung diseases. Patients should take the medicine as prescribed by the doctors and pay close attention to drug interactions, according to the administration. The administration asked the drug's marketing authorization holder to continue its relevant research work, fulfill the conditions within the specified time and submit the following research results timely. Five Chinese pharmaceutical companies have signed agreements with an UN-based organization to manufacture the generic version of Pfizer's oral pill. They are among the 35 global drug makers that have joined Medicines Patent Pool to increase access to lifesaving medicines. Zhejiang Jiuzhou Pharmaceutical will produce the drug substance, and the other Chinese companies will produce both the drug substance and the final product. 輝瑞（Pfizer）公司的第一批抗病毒藥物 Paxlovid 已於週四抵達中國，五家中國公司將生產該口服藥的仿製藥。 中國藥品監管機構於 2 月 11 日有條件地批准輝瑞公司的 Paxlovid COVID-19 藥丸的進口。 根據國家藥品監督管理局，該藥丸是一種小分子口服藥物，是抗病毒藥物 尼馬瑞韋片劑和利托那韋片劑的聯合包裝，適用於出現輕度至中度 COVID-19 症狀和更嚴重疾病風險較高的成年人。 它可以給予例如年老或患有慢性腎病、糖尿病、心血管疾病和慢性肺病的患者。 根據國家藥品監督管理局，患者應按醫囑服藥，密切注意藥物相互作用。 主管部門要求藥品上市許可持有人繼續開展相關研究工作，在規定時間內滿足條件，並及時提交以下研究成果。 五家中國製藥公司與一家聯合國組織簽署了生產輝瑞口服藥仿製藥的協議。 他們是加入藥品專利池以增加獲得救命藥品的 35 家全球製藥商之一。 浙江九洲藥業將生產原料藥，其他中國公司將同時生產原料藥和最終產品。 Mega projects in China 中國的大型項目 China Infrastructure 中國基礎設施 China Speed 中國速度 China Innovation 中國創新 Chinese Technology 中國技術 High speed train 高速火車 Bullet train 子彈頭列車 Fuxing High Speed Rail 復興高鐵 Mega Machines 超級機器 Aerial View 鳥瞰圖 The longest bridge in the world 世界上最長的橋 The tallest bridge in the world 世界上最高的橋樑 The highest bridge in the world 世界最高的橋樑 China Space Exploration 中國太空探索 China Space Station 中國空間站 Xiong'an New Area 雄安新區